Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial.
ovarian cancer
sentinel lymph node
surgical oncology
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
02
2020
revised:
18
03
2020
accepted:
23
03
2020
pubmed:
26
5
2020
medline:
2
10
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Early-stage ovarian cancer might represent an ideal disease scenario for sentinel lymph node application. Nevertheless, the published experience seems to be limited. Our objective was to assess the feasibility and safety concerns of sentinel lymph node biopsy in patients with clinical stage I-II ovarian cancer. We conducted a prospective cohort study of 20 patients with histologically confirmed ovarian cancer. A total of 20 patients were included in the analysis. Sentinel lymph nodes were detected in 14/15 (93%) pelvic and all 20 (100%) para-aortic regions. Five patients did not have utero-ovarian injection because of prior hysterectomy. The mean time from injection to sentinel lymph node resection was 53±15 min (range; 30-80). The mean number of harvested sentinel lymph nodes was 2.2±1.5 (range; 0-5) lymph nodes in the pelvis and 3.3±1.8 (range; 1-7) lymph nodes in the para-aortic region. There were no adverse intraoperative events, nor any within the 30 days of follow-up related with the technique. Sentinel lymph node mapping in early-stage ovarian cancer is feasible without major intraoperative or < 30 days safety concerns. (NCT03452982). ClinicalTrials.gov, NCT03452982.
Identifiants
pubmed: 32448808
pii: ijgc-2020-001289
doi: 10.1136/ijgc-2020-001289
pmc: PMC7497563
doi:
Banques de données
ClinicalTrials.gov
['NCT03452982']
EudraCT
['2017-003683-12']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1396Informations de copyright
© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: SD has received a speaker honorarium from Ethicon.
Références
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
Curr Opin Oncol. 2011 Sep;23(5):507-11
pubmed: 21602676
Int J Gynecol Cancer. 2016 Oct;26(8):1407-14
pubmed: 27465900
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
J Natl Cancer Inst. 2006 May 3;98(9):599-609
pubmed: 16670385
Int J Gynecol Cancer. 2019 Sep;29(7):1209-1215
pubmed: 31474589
J Nucl Med. 2014 Nov;55(11):1799-804
pubmed: 25332439
Int J Gynecol Cancer. 2019 Feb;29(2):377-381
pubmed: 30718316
J Clin Oncol. 2000 Aug;18(15):2811-6
pubmed: 10920128
Am J Obstet Gynecol. 2019 Oct;221(4):324.e1-324.e10
pubmed: 31082385
Int J Gynecol Cancer. 2018 May;28(4):641-655
pubmed: 29688967
N Engl J Med. 1990 Apr 12;322(15):1021-7
pubmed: 2181310
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):192-202
pubmed: 15823099
Int J Gynecol Cancer. 2011 Apr;21(3):568-72
pubmed: 21436705
J Minim Invasive Gynecol. 2020 Jul - Aug;27(5):1019-1020
pubmed: 31628986
Int J Gynecol Cancer. 2010 Oct;20(7):1142-7
pubmed: 21495216
J Minim Invasive Gynecol. 2017 Jan 1;24(1):165-170
pubmed: 27670732
Int J Gynecol Cancer. 2019 Nov;29(9):1449
pubmed: 31575615
Gynecol Oncol. 2000 Nov;79(2):251-5
pubmed: 11063653
Ann Surg Oncol. 2017 Sep;24(9):2720-2726
pubmed: 28608122
Br J Cancer. 2006 Sep 18;95(6):699-704
pubmed: 16940979
J Ovarian Res. 2016 Sep 07;9(1):55
pubmed: 27604260
Int J Gynecol Cancer. 2000 Nov;10(6):435-442
pubmed: 11240711
Lancet. 2001 Jan 20;357(9251):176-82
pubmed: 11213094
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S118-29
pubmed: 22999503
Gynecol Oncol. 2004 Jul;94(1):161-6
pubmed: 15262135
Gynecol Oncol. 2011 Dec;123(3):610-4
pubmed: 21982047
Int J Gynecol Cancer. 2017 May;27(4):684-689
pubmed: 28375928